GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coherus BioSciences Inc (FRA:8C5) » Definitions » Cash Paid for Insurance Activities

Coherus BioSciences (FRA:8C5) Cash Paid for Insurance Activities


View and export this data going back to 2014. Start your Free Trial

What is Coherus BioSciences Cash Paid for Insurance Activities?

Cash Paid for Insurance Activities only applicable to companies reporting Cash Flow from Operations in direct method.


Coherus BioSciences (FRA:8C5) Business Description

Industry
Traded in Other Exchanges
Address
333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States.